Infinity Pharmaceuticals
closedDiscovery and development of medicines for the treatment of cancer and related conditions.
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 267 % | (86 %) | (33 %) | - | 50 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (583 %) | (55 %) | (1500 %) | (1900 %) | (2250 %) | (1467 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (700 %) | (50 %) | (1567 %) | (2000 %) | (2250 %) | (1467 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 347 % | 90 % | 904 % | 1338 % | 1582 % | 1080 % |
Source: Company filings or news article
Related Content
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative cancer therapies. The company primarily targets the immune system to treat advanced melanoma and other malignancies. Operating in the biotechnology sector, Infinity Pharmaceuticals serves patients with severe cancer conditions, collaborating with leading medical institutions and researchers. The company’s business model revolves around the research, development, and commercialization of novel drugs. Revenue is generated through the sale of approved therapies and partnerships with other pharmaceutical companies. Infinity Pharmaceuticals leverages its scientific expertise and strategic collaborations to advance its drug pipeline, aiming to bring life-saving treatments to market.
Keywords: biopharmaceutical, cancer therapies, immune system, advanced melanoma, biotechnology, drug development, commercialization, strategic collaborations, novel drugs, life-saving treatments.
Tech stack
Investments by Infinity Pharmaceuticals
Edit